Tetra Discovery Advances Alzheimer’s Treatment Candidate BPN14770 to Phase I Multiple Ascending Dose Trial

Tetra Discovery Partners (“Tetra”) today announced that the company has successfully completed its initial Phase 1 single ascending dose (SAD) study of BPN14770 safety in 32 healthy volunteers. BPN14770 is the company’s experimental treatment aimed at improving memory and slowing the progression of Alzheimer’s disease. Tetra plans to begin its second Phase 1 trial of BPN14770 in June, which will study multiple ascending doses (MAD).

“We are very pleased with the excellent safety and pharmacology results seen in our initial SAD Phase 1 study of BPN14770 in healthy volunteers. BPN14770 showed linear dose proportionality, high estimated bioavailability, half-life adequate for once daily dosing, and relatively low variability between subjects,” said Mark Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra. “We believe this compound has the potential to benefit the lives of patients with Alzheimer’s disease as well as those with milder cognitive disorders, or with cognitive disorders that are part of other medical illnesses.
“The next study, to be conducted in approximately 80 healthy young and elderly volunteers, will examine both the safety and pharmacokinetics of multiple ascending doses of BPN14770 and seek an initial read out of its effects on cognition,” he added.

BPN14770 is a novel therapeutic agent that works through the PKA-CREB pathway to enhance synaptic action of the brain neurons involved in memory and cognition. This unique mechanism of action has the potential to improve cognitive and memory function in devastating disorders including Alzheimer’s disease, schizophrenia, and learning/developmental disabilities such as Fragile X syndrome. Tetra plans to evaluate the therapeutic potential of BPN14770 in reversing memory dysfunction as well as its ability to slow the progression of Alzheimer’s disease.

In the Multiple Ascending Dose trial (MAD), Tetra will study both young and elderly healthy volunteers who will receive daily doses of BPN14770. The subjects will be housed in a clinic setting and carefully monitored to detect any potential effects of the drug. In addition, elderly subjects will receive tests of their memory and cognitive ability throughout the dosing period. Particular attention will be paid to improvements in long-term memory, the key potential benefit of BPN14770. This study will pave the way for Phase 2 studies in patients with cognitive disorders including Alzheimer’s disease.

“We are hopeful that treatment with BPN14770 will lead to improved memory and cognition in individuals with non-amyloid or amyloid-related forms of dementia,” said Scott Reines, M.D., Ph.D., chief medical officer of Tetra.

Tetra thanks the National Institutes of Health and its innovative Blueprint Neurotherapeutics Program for their support and the active participation of the translational research experts that were involved in the BPN14770 project team, as well as the contracted drug discovery and development CROs who participated in this program.

Download PDF

Podcast

The Bio Report
January 2, 2020
Stabilizing Neuronal Connections to Treat Cognitive Impairment in Alzheimer’s

BioTech Nation Radio
April 3, 2019
Treatments for Fragile X, Alzheimer’s disease, and traumatic brain injury.

Awards

Michigan Celebrates
May 3, 2018
Michigan 50 Company to Watch 2018

GRBJ
December 12, 2016
2016 Newsmaker of the Year finalists

PM360
December 21, 2016
Innovators 2016: Startups

In The News

July 12, 2022

Tetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome

July 23, 2021

Tetra Therapeutics CEO Mark Gurney retires

July 23, 2021

Tetra Therapeutics Announces Retirement of Mark Gurney and Names Chad Coberly Chief Executive Officer in Planned Succession

July 11, 2021

Decades-long quest to beat Fragile X fueled by persistence, science and relentless optimism

April 30, 2021

Experimental Treatment Boosts Cognitive Function in Fragile X Syndrome

NPR

April 29, 2021

Memory Loss Drug Appears To Help People With The Genetic Disease Fragile X

April 29, 2021

Treatment Found to Improve Cognitive Function in Patients With Fragile X Syndrome

April 29, 2021

Drug boosts cognition in men with fragile X syndrome

April 29, 2021

Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial

April 29, 2021

Fragile X Treatment Shows Promise in Phase II Trial

April 22, 2021

Researchers take a big step in treating a genetic disorder closely linked to autism.

February 9, 2021

People with dementia had significantly greater risk of contracting the coronavirus.

February 9, 2021

Research documents more cases, hospitalizations and deaths.

December 11, 2020

New drug moves closer to becoming first treatment for Fragile X Syndrome

More News

Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA

OSAKA, Japan, September 27, 2023 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the U.S. Food and Drug Administration (FDA) has granted Tetra Therapeutics Inc. (hereafter “Tetra”), a Shionogi Group Company, Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational

Read More »

Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in Patients with Fragile X Syndrome

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–Tetra Therapeutics, a wholly owned subsidiary of Shionogi & Co. Ltd., today announced positive topline results from its Phase 2 exploratory study in adult patients with Fragile X Syndrome (FXS). The study evaluated its lead candidate, BPN14770, a first-in-class phosphodiesterase‐4D (PDE4D) allosteric inhibitor. In this single-center, randomized,

Read More »